Viatris Collaborates with Idorsia to Develop and Commercialize Selatogrel and Cenerimod
Shots:
- Viatris & Idorsia have signed a global R&D collaboration agreement for 2 P-III assets, selatogrel (for AMI) & cenerimod (for SLE)
- Viatris will be responsible for product development & personnel and gets global commercialization rights for the assets (excl. Japan, South Korea & specific Asia-Pacific countries for cenerimod) with first refusal & negotiation rights for other assets in Idorsia's pipeline
- Idorsia will receive an upfront payment of $350M, development & regulatory milestones, contingent payments for sales milestones plus mid-single to low-double digit percentages net sales-based tiered royalties. Both the companies will contribute to the development & a joint development committee will manage the P-III programs
Ref: Viatris | Image: Viatris
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
